SeekingAlpha · Mar 8, 2026
Invivyd, Inc. 2025 Q4 - Results - Earnings Call Presentation
2026-03-08. The following slide deck was published by Invivyd, Inc.
IV
NASDAQ · IVVD
Invivyd, Inc.
Healthcare · Biotechnology
$0.83
Down-$0.06 (-6.93%)
Updated Sep 16, 2026, 11:01 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 317.89M
- P/E ratio
- -6.81
- Dividend yield
- 0.00%
- 52-week range
- $0.53 – $3.07
- Volume
- 4.23M
- Avg. volume
- 7.17M
Price performance
IVVD price history
1M range · 20 trading sessions · Daily adjusted prices
IVVD closed at $0.83 after 20 trading sessions, down 4.39% for the selected period.
- Last close
- $0.83
- Period change
- -4.39%
- Period low
- $0.78
- Period high
- $1.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $0.8812 | $0.893 | $0.82 | $0.83 | 4.23M |
| Sep 14, 2026 | $0.82 | $0.9361 | $0.8021 | $0.8918 | 3.8M |
| Sep 11, 2026 | $0.7901 | $0.8174 | $0.7711 | $0.7855 | 4.38M |
| Sep 10, 2026 | $0.7822 | $0.8151 | $0.7703 | $0.7759 | 1.9M |
| Sep 9, 2026 | $0.8177 | $0.822 | $0.7833 | $0.7973 | 1.91M |
| Sep 8, 2026 | $0.849 | $0.8626 | $0.8097 | $0.8258 | 2.09M |
| Sep 4, 2026 | $0.82 | $0.8269 | $0.7901 | $0.826 | 1.96M |
| Sep 3, 2026 | $0.8346 | $0.8471 | $0.8025 | $0.835 | 2.58M |
| Sep 2, 2026 | $0.8685 | $0.8798 | $0.78 | $0.804 | 4.99M |
| Sep 1, 2026 | $0.86 | $0.9013 | $0.753 | $0.8799 | 12.58M |
| Aug 31, 2026 | $0.996 | $1.01 | $0.9423 | $0.9549 | 3.5M |
| Aug 28, 2026 | $0.91 | $0.97 | $0.894 | $0.9645 | 3.63M |
| Aug 27, 2026 | $0.90 | $0.916 | $0.8788 | $0.9001 | 1.72M |
| Aug 26, 2026 | $0.9232 | $0.9232 | $0.8434 | $0.9017 | 3.63M |
| Aug 25, 2026 | $0.9256 | $0.9797 | $0.9217 | $0.9387 | 2.85M |
| Aug 24, 2026 | $0.97 | $0.975 | $0.91 | $0.9425 | 4.06M |
| Aug 21, 2026 | $0.945 | $1.03 | $0.8664 | $0.9965 | 5.43M |
| Aug 20, 2026 | $1.015 | $1.05 | $0.9336 | $0.9508 | 8.55M |
| Aug 19, 2026 | $0.8883 | $1.01 | $0.8883 | $0.9595 | 7.26M |
| Aug 18, 2026 | $0.76 | $0.8747 | $0.752 | $0.8681 | 7.75M |
Latest IVVD news
The latest Smart Investors Daily articles mentioning IVVD.
Stock researchCompany · Overview
IVVD research
Overview
Company profile and research snapshot.
Company profile
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | BTIG | Buy | — |
| Aug 27, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 7, 2026 | BTIG | Buy | — |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 9, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 5, 2026
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Benzinga · Mar 5, 2026
Invivyd Q4 Earnings Assessment
Benzinga · Mar 5, 2026
Invivyd Q4 EPS $0.02 Beats $(0.08) Estimate, Sales $17.207M Beat $15.525M Estimate
Invivyd (NASDAQ:IVVD) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.08) by 124.1 percent. This is a 113.33 percent increase over losses of $(0.15) per share from the same
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
